BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37680151)

  • 21. A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma.
    Fang X; Huang E; Xie X; Yang K; Wang S; Huang X; Song M
    Front Genet; 2022; 13():951311. PubMed ID: 36406130
    [No Abstract]   [Full Text] [Related]  

  • 22. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma.
    Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S
    Front Genet; 2022; 13():862741. PubMed ID: 35368663
    [No Abstract]   [Full Text] [Related]  

  • 23. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.
    Ren J; Wang A; Liu J; Yuan Q
    Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methylation of N6 adenosine-related long noncoding RNA: effects on prognosis and treatment in 'driver-gene-negative' lung adenocarcinoma.
    Yang HS; Cai HY; Shan SC; Chen TF; Zou JY; Abudurufu M; Luo HH; Lei YY; Ke ZF; Zhu Y
    Mol Oncol; 2023 Feb; 17(2):365-377. PubMed ID: 36221911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
    Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T
    Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma.
    Li S; Wang W; Yu H; Zhang S; Bi W; Sun S; Hong B; Fang Z; Chen X
    BMC Cancer; 2023 Nov; 23(1):1115. PubMed ID: 37974107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitochondria-related lncRNAs: predicting prognosis, tumor microenvironment and treatment response in lung adenocarcinoma.
    Zhou Q; Xiong J; Gao Y; Yi R; Xu Y; Chen Q; Wang L; Chen Y
    Funct Integr Genomics; 2023 Oct; 23(4):323. PubMed ID: 37864709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel algorithm for lung adenocarcinoma based on N6 methyladenosine-related immune long noncoding RNAs as a reliable biomarker for predicting survival outcomes and selecting sensitive anti-tumor therapies.
    Yan Q; Hu B; Chen H; Zhu L; Lyu Y; Qian D; Shao G
    J Clin Lab Anal; 2022 Sep; 36(9):e24636. PubMed ID: 35949000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
    Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
    J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of an invasion score based on metastasis-related pathway activity profiles for identifying invasive molecular subtypes of lung adenocarcinoma.
    Han T; Liu Y; Zhou J; Guo J; Xing Y; Xie J; Bai Y; Wu J; Hu D
    Sci Rep; 2024 Jan; 14(1):1692. PubMed ID: 38243040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comprehensive Analysis of the Relationship between m6A Methylation Patterns and Immune Microenvironment in Lung Adenocarcinoma].
    Ke J; Cui J; Yang X; Du X; Ma B; Yu L
    Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):311-322. PubMed ID: 35599007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
    Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel cuproptosis-related lncRNA signature to predict prognosis and immune landscape of lung adenocarcinoma.
    Wang X; Jing H; Li H
    Transl Lung Cancer Res; 2023 Feb; 12(2):230-246. PubMed ID: 36895935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
    Li F; Niu Y; Zhao W; Yan C; Qi Y
    Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
    Liang H; Li Y; Qu Y; Zhang L
    Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular typing and prognostic model of lung adenocarcinoma based on cuprotosis-related lncRNAs.
    Zheng M; Zhou H; Xie J; Zhang H; Shen X; Zhu D
    J Thorac Dis; 2022 Dec; 14(12):4828-4845. PubMed ID: 36647499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma.
    Cao K; Liu M; Ma K; Jiang X; Ma J; Zhu J
    Cancer Immunol Immunother; 2022 Jun; 71(6):1295-1311. PubMed ID: 34652523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Characterization and Prognosis of Lactate-Related Genes in Lung Adenocarcinoma.
    Guo Z; Hu L; Wang Q; Wang Y; Liu XP; Chen C; Li S; Hu W
    Curr Oncol; 2023 Feb; 30(3):2845-2861. PubMed ID: 36975430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.